Physician profile
Peter E Blosser
NPI 1114554581
$2,102.81
in general payments reported to CMS, 2019-2025
17 companies · $639 in 2025
The $639 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $155 · 2022: $545 · 2023: $365 · 2024: $398 · 2025: $639.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,402.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,402.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $710.38 | 2021-2025 | Clareon Panoptix Pro, Clareon, Argos |
| Genentech, INC. | $250.74 | 2022-2023 | Vabysmo |
| Sun Pharmaceutical Industries INC. | $125.47 | 2024-2025 | |
| Apellis Pharmaceuticals, INC. | $125.00 | 2022 | |
| Genentech USA, INC. | $120.74 | 2023 | Vabysmo |
| Sight Sciences, INC. | $118.17 | 2024-2025 | Omni Surgical System, Sion Surgical Instrument |
| Rxsight INC | $105.45 | 2024 | Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens, Light Adjustable Lens (Lal) |
| Regeneron Pharmaceuticals, INC. | $96.54 | 2022 | |
| Astellas Pharma US INC | $88.27 | 2025 | Izervay |
| Tarsus Pharmaceuticals, INC. | $84.58 | 2024-2025 | Xdemvy |
| Abbvie INC. | $79.03 | 2022 | |
| Bausch & Lomb Americas INC. | $64.18 | 2025 | Xiidra, Miebo, Envista Envy Iol |
| Dompe US, INC. | $42.22 | 2024-2025 | Oxervate |
| Glaukos Corporation | $31.56 | 2025 | Idosetr |
| Mallinckrodt Hospital Products INC. | $22.86 | 2024 | Acthar |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $19.44 | 2025 | Tepezza |
| Ocular Therapeutix, INC. | $18.18 | 2025 | Dextenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Blosser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.